DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
Public ClinicalTrials.gov record NCT00224081. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Dialysis Patients' Response to IV Iron With Elevated Ferritin
Study identification
- NCT ID
- NCT00224081
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Enrollment
- 134 participants
Conditions and interventions
Interventions
- Sodium ferric gluconate, Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2004
- Primary completion
- Apr 30, 2006
- Completion
- Not listed
- Last update posted
- Dec 9, 2015
Started 2004
United States locations
- U.S. sites
- 29
- U.S. states
- 16
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Bakersfield | California | — | — |
| Not listed | Glendale | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Santa Rosa | California | — | — |
| Not listed | Torrance | California | — | — |
| Not listed | Lauderdale Lakes | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Roswell | Georgia | — | — |
| Not listed | Waycross | Georgia | — | — |
| Not listed | Crestwood | Illinois | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Kalamazoo | Michigan | — | — |
| Not listed | Royal Oak | Michigan | — | — |
| Not listed | Columbia | Missouri | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | North Brunswick | New Jersey | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | Minneola | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Youngstown | Ohio | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00224081, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 9, 2015 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00224081 live on ClinicalTrials.gov.